Paola Francica

Paola Francica

Auto-generated profile, based on publicly available information

Paola Francica

University of Bern

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
MMMichaela Medova
Michaela Medova
BPBenoît Pochon
Benoît Pochon
BSBruno Streit
Bruno Streit
WBWieslawa Blank-Liss
Wieslawa Blank-Liss
PFPaola Francica
Paola Francica
ZYZimmer Yitzhak
Zimmer Yitzhak
The receptor tyrosine kinase MET is a prime target in clinical oncology due to its aberrant activation and involvement in the pathogenesis of a broad spectrum of malignancies. Similar to other targeted kinases, primary and secondary mutations seem to represent an important resistance mechanism to MET inhibitors. Here, we report the biologic activity of a novel MET inhibitor, EMD1214063, on cells that ectopically express the mutated MET variants M1268T, Y1248H, H1112Y, L1213V, H1112L, V1110I, V1206L, and V1238I. Our results show a dose-dependent decrease in MET autophosphorylation in response to EMD1214063 in five of the eight cell lines (IC50 2–43 nmol/L). Blockade of MET by EMD1214063 was accompanied by a reduced activation of downstream effectors in cells expressing EMD1214063-sensitive mutants. In all sensitive mutant-expressing lines, EMD1214063 altered cell-cycle distribution, primarily with an increase in G1 phase. EMD1214063 strongly influenced MET-driven biologic functions, such as cellular morphology, MET-dependent cell motility, and anchorage-independent growth. To assess the in vivo efficacy of EMD1214063, we used a xenograft tumor model in immunocompromised mice bearing NIH3T3 cells expressing sensitive and resistant MET-mutated variants. Animals were randomized for the treatment with EMD1214063 (50 mg/kg/d) or vehicle only. Remarkably, five days of EMD1214063 treatment resulted in a complete regression of the sensitive H1112L-derived tumors, whereas tumor growth remained unaffected in mice with L1213V tumors and in vehicle-treated animals. Collectively, the current data identifies EMD1214063 as a potent MET small-molecule inhibitor with selective activity towards mutated MET variants. Mol Cancer Ther; 12(11); 2415–24. ©2013 AACR.

17 December 2025 in Oncogene
Verified
Journal Article
Open access
PDF file
HDHülya Dogan
Hülya Dogan
MLMartin Liptay
Martin Liptay
JBJoana S. Barbosa
Joana S. Barbosa
EGEwa Gogola
Ewa Gogola
ADAlexandra A. Duarte
Alexandra A. Duarte
SRSven Rottenberg
Sven Rottenberg
MDC1 is a key protein in DNA damage signaling. When DNA double-strand breaks (DSBs) occur, MDC1 localizes to the sites of DNA damage to promote the recruitment of other factors, including the 53BP1-mediated DSB repair pathway. By studying mechanisms of poly (ADP-ribose) polymerase inhibitor (PARPi) resistance in BRCA2; p53-deficient mouse mammary tumors, we identified a thus far unknown role of MDC1 in replication fork biology. Our results show that MDC1 localizes at active replication forks during normal DNA replication and regulates replication fork progression. It suppresses spontaneous fork reversal and regulates fork nucleolytic processing thereby promoting sensitivity to PARPi and cisplatin. In this way, MDC1 loss improves DNA damage tolerance and causes chemoresistance in BRCA1/2-deficient cells. We demonstrate that limiting MRE11 activity abolishes the reduced fork speed while MRE11 inhibition/depletion overcomes PARPi resistance in these cells. Overall, our data provides new insights into the role of MDC1 in replication fork progression that mediates PARPi- and cisplatin-induced DNA damage, in addition to its role in DSB repair.

15 October 2025 in bioRxiv
Verified
Preprint
Open access
LLLea Lingg
Lea Lingg
MMMerve Mutlu
Merve Mutlu
ANArunasalam Naguleswaran
Arunasalam Naguleswaran
IKIsmar Klebic
Ismar Klebic
EGEwa Gogola
Ewa Gogola
PFPaola Francica
Paola Francica
BRCA1/2-deficient cells are hypersensitive to replication stress- and DNA-damage-inducing agents such as poly(ADP-ribose) polymerase inhibitors (PARPi), platinum drugs, and ionizing radiation (IR), largely due to impaired homologous recombination repair and replication fork (RF) protection. The precise mechanisms underlying RF vulnerability in the absence of BRCA1/2 remain incompletely understood, however. Here, we identify Thousand And One Amino Acid Kinase 1 (TAOK1) as a novel regulator of RF dynamics that sensitizes BRCA1/2-deficient cells to both PARPi and IR. Unlike established DNA repair factors, such as PARG or the 53BP1-RIF1-shieldin-CST pathway, which mediate PARPi sensitivity while protecting cells against IR, TAOK1 promotes RF degradation and suppresses post-replicative damage repair. TAOK1 depletion stabilizes RFs and reduces replication-associated DNA damage in BRCA1/2-deficient cells, thereby conferring therapy resistance. Interestingly, we found that TAOK1 functions in RF regulation to be independent of its kinase activity. Instead, it interacts with PCNA and regulates ISG15 levels and thereby affects RF stability. Our findings reveal TAOK1 as a non-canonical mediator of therapy sensitivity in BRCA1/2-deficient tumors. Teaser: TAOK1 controls replication fork stability through PCNA and ISG15, affecting therapy response in BRCA1/2-deficient cancers.

6 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
DSDilara Akhoundova Sanoyan
Dilara Akhoundova Sanoyan
MGMartín González-Fernández
Martín González-Fernández
ABAavash Baral
Aavash Baral
ABAndrej Benjak
Andrej Benjak
CPCarmen Perry
Carmen Perry
MRMark A. Rubin
Mark A. Rubin
Loss-of-function genomic alterations in FANCA occur across multiple cancer types, yet no molecularly tailored therapies have successfully exploited this potential vulnerability. Using complementary unbiased approaches, including a genome-wide CRISPR/Cas9 loss-of-function screen and a high-throughput drug screen in isogenic cancer cell-based models, we identified Aurora kinase A (AURKA) as a reproducible synthetic lethal target of FANCA-deficient cancers. Inhibition of AURKA induced chromosomal instability, micronucleation, and early G2/M arrest selectively in FANCA-deficient cells, consistent with an increased reliance on mitotic checkpoint control. Mechanistically, FANCA deficiency is associated with an elevated AURKA expression at both the transcriptomic and protein levels, and with an upregulation of mitotic spindle and G2/M checkpoint gene signatures. Analysis of large-scale cancer genomics datasets, including over 650,000 clinically sequenced tumors, confirms that FANCA is the most frequently altered Fanconi anemia pathway gene across cancers, and that Fanconi anemia–defective tumors exhibit an increased tumor mutational burden and genomic instability. Collectively, our findings point to AURKA inhibition as a promising precision treatment strategy in FANCA-deficient cancers and provide a rationale to further explore this strategy in the clinic.

7 August 2026 in Research Square
Verified
Preprint
Open access
PDF file
Andrea MorandiAndrea Morandi
Andrea Morandi
NLNicla Lorito
Nicla Lorito
ERElisabetta Romano
Elisabetta Romano
ASAlfredo Smiriglia
Alfredo Smiriglia
MBMarina Bacci
Marina Bacci
PFPaola Francica
Paola Francica
ER+/HER2 − breast cancer is commonly treated with endocrine therapy combined with CDK4/6 inhibitors (CDK4/6i), including palbociclib, ribociclib, and abemaciclib. Although these combinations have improved clinical outcome, resistance remains frequent, highlighting the need to identify vulnerabilities that enhance CDK4/6i response. To uncover metabolic dependencies associated with CDK4/6i sensitivity, we performed an unbiased loss-of-function screen targeting ∼2,800 metabolic genes. This identified lipase H (LIPH), a phosphatidic acid-selective phospholipase A1 that generates lysophosphatidic acid (LPA), as a candidate vulnerability in palbociclib-treated ER+/HER2- breast cancer cells. LIPH depletion reduced LPA levels and sensitized multiple ER+ models to palbociclib, ribociclib, and abemaciclib. Mechanistically, LIPH-derived LPA activated LPAR2-dependent AMPK/p38 signaling, sustaining CD36 expression. CD36 regulated cyclin D1 levels and cell-cycle progression, while LIPH or CD36 depletion reduced cyclin D1, induced G0/G1 accumulation, and enhanced CDK4/6i sensitivity. Conversely, exogenous LPA restored CD36 and cyclin D1 expression in LIPH-silenced cells. Genetic or pharmacological CD36 targeting potentiated CDK4/6i efficacy in endocrine-sensitive and therapy-resistant ER+ models, as well as in patient-derived organoids. Clinically, high LIPH/CD36 scores were associated with poor response to CDK4/6i-based therapy, while elevated LIPH, CD36, or combined LIPH/LPAR2/CD36 expression correlated with worse outcome in ER+/HER2 − breast cancer cohorts. Together, our findings identify the LIPH–LPA–LPAR2–CD36–cyclin D1 axis as a lipid-signaling vulnerability that modulates CDK4/6i response and propose LIPH and CD36 as candidate therapeutic targets and biomarkers in ER+/HER2- breast cancer.